SmithKline Nicorette second quarter U.S. sales up 9%, but NicoDerm CQ sales fall 18%.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE NICORETTE SECOND QUARTER SALES INCREASE 9% in the U.S., while sales for NicoDerm CQ fell 18% during the period, SmithKline Beecham said July 21. Helped by the Nicorette nicotine gum increase, the company maintained its 94.4% share of the U.S. OTC smoking cessation market for the quarter. However, U.S. sales for SmithKline's OTC drug products decreased 1% to $517 mil. for the same period.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning